Seroepidemiology of human papillomavirus 16 (HPV16) L2 and generation of L2-specific human chimeric monoclonal antibodies

Clinical and Vaccine Immunology

Volumn 22, Issue 7, 2015, Pages 806-816

  Wang, Joshua W ^a   Jagu, Subhashini ^a   Wu, Wai Hong ^a   Viscidi, Raphael P ^a   Macgregor Das, Anne ^a   Fogel, Jessica M ^a   Kwak, Kihyuck ^a   Daayana, Sai ^c   Kitchener, Henry ^c   Stern, Peter L ^c   Gravitt, Patti E ^d   Trimble, Cornelia L ^a,b   Roden, Richard B S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMIQUIMOD; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JWW 1; MONOCLONAL ANTIBODY JWW 2; UNCLASSIFIED DRUG; WART VIRUS VACCINE; CAPSID PROTEIN; HYBRID PROTEIN; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; VIRUS ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 16 L2; HUMAN TISSUE; IMMUNOASSAY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHOTODYNAMIC THERAPY; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS NEUTRALIZATION; WESTERN BLOTTING; AGED; BLOOD; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SERODIAGNOSIS; SEROLOGY; STANDARDS; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CAPSID PROTEINS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS;

EID: 84936857890     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00799-14     Document Type: Article

References (50)

1. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342-350. http://dx.doi.org/10.1038/nrc798.
2. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJF, Peto J, Meijer CJLM, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19. http://dx.doi.org/10.1002/(SICI)1096-9896(199909) 189:1-12::AID-PATH431-3.0.CO;2-F.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907. http://dx.doi.org/10.1016/S0140-6736(07)61416-0.
4. Schiller JT, Castellsague X, Garland SM. 2012. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5): F123-F138. http://dx.doi.org/10.1016/j.vaccine.2012.04.108.
5. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPV Vaccine Study Group. 2015. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711-723. http://dx.doi.org/10.1056/NEJMoa1405044.
6. Schabath MB, Villa LL, Lin HY, Fulp WJ, Akogbe GO, Abrahamsen ME, Papenfuss MR, Lazcano-Ponce E, Salmeron J, Quiterio M, Giuliano AR. 2013. Racial differences in the incidence and clearance of human papilloma virus (HPV): the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev 22:1762-1770. http://dx.doi.org/10.1158/1055 -9965.EPI-13-0303.
7. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Steinau M, Markowitz LE, HPV-IMPACT Working Group. 2012. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J Infect Dis 206:1878-1886. http://dx.doi.org/10.1093/infdis/jis627.
8. Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, McBride V, Markowitz LE, Unger ER, Hadler JL, Sosa LE. 2013. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: associations with race, ethnicity, and poverty. Cancer 119: 3052-3058. http://dx.doi.org/10.1002/cncr.28038.
9. Agosti JM, Goldie SJ. 2007. Introducing HPV vaccine in developing countries- key challenges and issues. N Engl J Med 356:1908-1910. http://dx.doi.org/10.1056/NEJMp078053.
10. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, HPV PATRICIA Study Group. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:100-110. http://dx.doi.org/10.1016/S1470-2045(11)70287-X.
11. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. 2012. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:781-789. http://dx.doi.org/10.1016/S1473-3099(12)70187-1.
12. Christensen ND, Kreider JW, Kan NC, DiAngelo SL. 1991. The open reading frame L2 of cottontail rabbit papillomavirus contains antibodyinducing neutralizing epitopes. Virology 181:572-579. http://dx.doi.org/10.1016/0042-6822(91)90890-N.
13. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB. 2007. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81:11585-11592. http://dx.doi.org/10.1128/JVI.01577-07.
14. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RBS. 2007. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81:13927-13931. http://dx.doi.org/10.1128/JVI.00936-07.
15. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RBS. 2009. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101:782-792. http://dx.doi.org/10.1093/jnci/djp106.
16. Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, Roden RB. 2013. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 8:e55538. http://dx.doi.org/10.1371/journal.pone.0055538.
17. Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang HK, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB. 2013. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol 87:6127-6136. http://dx.doi.org/10.1128/JVI.03218-12.
18. Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R. 2013. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 133:2706-2713. http://dx.doi.org/10.1038/jid.2013.253.
19. Schellenbacher C, Roden R, Kirnbauer R. 2009. Chimeric L1-L2 viruslike particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83:10085-10095. http://dx.doi.org/10.1128/JVI.01088-09.
20. Lehtinen M, Niemela J, Dillner J, Parkkonen P, Nummi T, Liski E, Nieminen P, Reunala T, Paavonen J. 1993. Evaluation of serum antibody response to a newly identified B-cell epitope in the minor nucleocapsid protein L2 of human papillomavirus type 16. Clin Diagn Virol 1:153-165. http://dx.doi.org/10.1016/0928-0197(93)90010-3.
21. Jenison SA, Yu XP, Valentine JM, Galloway DA. 1991. Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18. J Virol 65:1208-1218.
22. Jenison SA, Firzlaff JM, Langenberg A, Galloway DA. 1988. Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol 62:2115-2123.
23. Yaegashi N, Jenison SA, Batra M, Galloway DA. 1992. Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11. J Virol 66:2008-2019.
24. Kanda T, Teshima H, Katase K, Umezawa S, Watabe H, Takahashi H, Onda T, Yoshiike K. 1995. Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia. Intervirology 38:187-191.
25. Suchánková A, Ritter O, Hirsch I, Krchnák V, Kalos Z, Hamsíková E, Brichácek B, Vonka V. 1990. Presence of antibody reactive with synthetic peptide derived from L2 open reading frame of human papillomavirus types 6b and 11 in human sera. Acta Virol 34:433-442.
26. Paez CG, Yaegashi N, Sato S, Yajima A. 1993. Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. Tohoku J Exp Med 170:113-121. http://dx.doi.org/10.1620/tjem.170.113.
27. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. 2012. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 19: 1075-1082. http://dx.doi.org/10.1128/CVI.00139-12.
28. Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Müller L, Pawlita M, Müller M. 2013. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 8:e75677. http://dx.doi.org/10.1371/journal.pone.0075677.
29. Wang JW, Jagu S, Kwak K, Wang C, Peng S, Kirnbauer R, Roden RB. 2014. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology 449:304-316. http://dx.doi.org/10.1016/j.virol.2013.10.038.
30. Ferguson M, Wilkinson DE, Zhou T. 2009. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 27:337-347. http://dx.doi.org/10.1016/j.vaccine.2008.10.062.
31. Wilkinson DEH, Heath AB, Faust H, Panicker G, Unger ER, Dillner J, Ngamkham J, Collaborative Study Group. 2012. Collaborative study to evaluate the proposed 1st WHO international standard for antibodies to human papillomavirus type 18. WHO/BS/2012.2191. World Health Organization, Geneva, Switzerland. https://extranet.who.int/iris/restricted/bitstream/10665/96608/1/WHO-BS-2012.2191-eng.pdf.
32. Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, Kalpana B, Ronnett BM, Vijayaraghavan K, Shah KV, CATCH Study Team. 2010. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One 5:e13711. http://dx.doi.org/10.1371/journal.pone.0013711.
33. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D. 2005. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11:4717-4723. http://dx.doi.org/10.1158/1078-0432.CCR-04-2599.
34. Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, Kitchener HC. 2008. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res 14:5292-5299. http://dx.doi.org/10.1158/1078-0432.CCR-07-4760.
35. Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC. 2010. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 102:1129-1136. http://dx.doi.org/10.1038/sj.bjc.6605611.
36. Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, Sobel J, Shah KV. 2005. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14:283-288.
37. Roden RB, Yutzy WH, IV, Fallon R, Inglis S, Lowy DR, Schiller JT. 2000. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270:254-257. http://dx.doi.org/10.1006/viro.2000.0272.
38. Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB. 2014. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV pseudovirions. PLoS One 9:e101576. http://dx.doi.org/10.1371/journal.pone.0101576.
39. Nakao S, Mori S, Kondo K, Matsumoto K, Yoshikawa H, Kanda T. 2012. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology 434:110-117. http://dx.doi.org/10.1016/j.virol.2012.09.006.
40. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB. 2005. Crossneutralization of cutaneous and mucosal papillomavirus types with antisera to the amino terminus of L2. Virology 337:365-372. http://dx.doi.org/10.1016/j.virol.2005.04.011.
41. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. 2008. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 80:841-846. http://dx.doi.org/10.1002/jmv.21124.
42. Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Torrimasino M, Muller M, Ottonello S. 2009. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -38) peptide displayed on bacterial thioredoxin. Vaccine 27:1949-1956. http://dx.doi.org/10.1016/j.vaccine.2009.01.102.
43. Tumban E, Peabody J, Peabody DS, Chackerian B. 2011. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly crossneutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 6:e23310. http://dx.doi.org/10.1371/journal.pone.0023310.
44. Embers ME, Budgeon LR, Pickel M, Christensen ND. 2002. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 76:9798-9805. http://dx.doi.org/10.1128/JVI.76.19.9798-9805.2002.
45. Campo MS, Grindlay GJ, O?Neil BW, Chandrachud LM, McGarvie GM, Jarrett WF. 1993. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74(Pt 6):945-953.
46. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RBS. 2006. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66:11120-11124. http://dx.doi.org/10.1158/0008-5472.CAN-06-2560.
47. Kawana K, Yasugi T, Kanda T, Kino N, Oda K, Okada S, Kawana Y, Nei T, Takada T, Toyoshima S, Tsuchiya A, Kondo K, Yoshikawa H, Tsutsumi O, Taketani Y. 2003. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21:4256-4260. http://dx.doi.org/10.1016/S0264-410X(03)00454-7.
48. Wang JW, Jagu S, Wang CG, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RBS. 2014. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV pseudovirions. PLoS One 9:e101576. http://dx.doi.org/10.1371/journal.pone.0101576.
49. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. 2008. Arrangement of L2 within the papillomavirus capsid. J Virol 82:5190-5197. http://dx.doi.org/10.1128/JVI.02726-07.
50. World Health Organization. 2006. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus-like particle vaccines. WHO/BS/06.2050. World Health Organization, Geneva, Switzerland. http://www.who.int/immunization/hpv/learn/guidelines-to-assure-the-quality-safety-and-efficacity-ecbs-2006.pdf.